Financial Lp Hrt Buys 14,556 Shares of Profusa (NASDAQ:PFSA) Stock

Posted by on Aug 7th, 2026

Profusa, Inc. (NASDAQ:PFSA – Get Free Report) major shareholder Financial Lp Hrt acquired 14,556 shares of the stock in a transaction that occurred on Monday, August 3rd. The shares were bought at an average cost of $0.96 per share, for a total transaction of $13,973.76. Following the completion of the transaction, the insider directly owned 108,301 shares of the company’s stock, valued at $103,968.96. This represents a 15.53% increase in their position. The purchase was disclosed in a document filed with the SEC, which is available through this hyperlink. Large shareholders that own 10% or more of a company’s stock are required to disclose their sales and purchases with the SEC.

Financial Lp Hrt also recently made the following trade(s):

  • On Tuesday, August 4th, Financial Lp Hrt acquired 1,368 shares of Profusa stock. The stock was bought at an average price of $0.95 per share, for a total transaction of $1,299.60.
  • On Wednesday, July 29th, Financial Lp Hrt bought 1,310 shares of Profusa stock. The stock was bought at an average price of $1.01 per share, with a total value of $1,323.10.

Profusa Stock Down 0.2%

Shares of NASDAQ:PFSA opened at $0.94 on Friday. The firm has a fifty day moving average of $3.57 and a two-hundred day moving average of $32.18. The firm has a market capitalization of $178,410.00, a P/E ratio of -0.00 and a beta of 0.52. Profusa, Inc. has a 12-month low of $0.86 and a 12-month high of $1,297.50.

Analysts Set New Price Targets

PFSA has been the subject of a number of research reports. Wall Street Zen raised Profusa from a “strong sell” rating to a “sell” rating in a research report on Saturday, April 18th. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Profusa in a research report on Wednesday, June 24th. One investment analyst has rated the stock with a Sell rating, According to data from MarketBeat, the company presently has a consensus rating of “Sell”.

View Our Latest Report on Profusa

Profusa Company Profile

(Get Free Report)

Profusa develops implantable, tissue-integrated biosensors and associated reader technology designed to provide continuous, real-time monitoring of physiological biomarkers. Its platform uses a biocompatible, porous hydrogel sensor that is placed under the skin via a minimally invasive procedure and becomes perfused with tissue; an external optical reader interrogates the sensor to convert fluorescent or optical signals into quantitative measurements such as local tissue oxygen levels. The company’s approach emphasizes long-duration sensing from a single implanted device rather than repeated spot measurements.

The technology is being positioned to support a range of clinical and commercial applications, including chronic disease management, wound and post-surgical monitoring, and clinical research where continuous molecular-level data can improve decision-making.

Recommended Stories

Receive News & Ratings for Profusa Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Profusa and related companies with MarketBeat.com's FREE daily email newsletter.